Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2021, 30(3):175-184

Biomarkers in heart failure. From well-established to promising

Chudý M, Lesný P, Goncalvesová E
Kardiologická klinika LFUK a NÚSCH, a. s., Bratislava, Slovenská republika

The importance of biomarkers is continuously growing in all fields of medicine. Their significance does not lie in diagnosis and prognosis evaluation only: they contribute moreover to reveal novel signaling pathways which are becoming new potential therapeutic targets. Because of the complexity of heart failure syndrome, the wide spectrum of biomarkers representing several pathophysiological processes has to be studied and analysed. These biomarkers include myocardial damage, overload and remodeling markers, peripheral organs´ damage biomarkers and on the genetic level also post-transcriptional regulators of gene expression - so-called microRNA. Evaluation of a broad panel of biomarkers is likely to be an essential part of heart failure phenotype determination and treatment strategy personalisation in the future. The article brings a brief summary of biomarkers used in clinical practice with focus mainly on those which may have a qualitatively different value for treatment individualization. Fig. 2.

Keywords: heart failure; biomarkers; mikro-RNA; microbiome; NT-proBNP

Published: March 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chudý M, Lesný P, Goncalvesová E. Biomarkers in heart failure. From well-established to promising. Cardiology Letters. 2021;30(3-4):175-184.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: A systematic review 2004-2016. BMC Cardiovasc Disord. 2018; May 2;18:74. Go to original source...
    2. Korewicki J. Cardiac transplantation is still the method of choice in the treatment of patients with severe heart failure. Cardiol J. 2009;16:493-499.
    3. Atkinson AJ, Colburn WA, DeGruttola, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:9-95. Go to original source...
    4. Sarhene M, Wang Y, Wei J, et al. Biomarkers in heart failure: the past, current and future. Heart Failure Reviews. 2019;24:867-903. Go to original source...
    5. Nadar SK, Shaikh MM. Biomarkers in routine heart failure clinical care. Card Fail Rev. 2019; Feb 11;5:50-56. Go to original source...
    6. Sachdeva A, Horwich TB, Fonarow GC. Comparison of usefulness of each of five predictors of mortality and urgent transplantation in patients with advanced heart failure. Am J Cardiol. 2010; Sep 15;106:830-835. Go to original source...
    7. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004; Oct 12;110:21682174. Go to original source...
    8. Cleland JGF, McMurray JJV, Kjekshus J, et al. Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin. A Report From CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009; Nov 10;54:1850-1859. Go to original source...
    9. Masson S, Latini R, Carbonieri E, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: Data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 2010; Apr;12:338-347. Go to original source...
    10. Shah RV, Truong QA, Gaggin HK, et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012; Sep;33:2197-2205. Go to original source...
    11. Wesseling M, de Poel JHC, de Jager SCA. Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player. ESC Heart Failure. 2020;7:1488-1501. Go to original source...
    12. Sukova J, Ostadal P, Widimsky P. Profile of patients with acute heart failure and elevated troponin I levels. Exp Clin Cardiol. 2007;12:153-156.
    13. Perna ER, Macín SM, Canella JPC, et al. Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. Int J Cardiol. 2005; Mar 18;99:253-261. Go to original source...
    14. Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008; May 15;358:2117-2126. Go to original source...
    15. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007; Sep;116:1242-1249. Go to original source...
    16. Masson S, Anand I, Favero C, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: Data from 2 large randomized clinical trials. Circulation. 2012; Jan 17;125:280-288. Go to original source...
    17. Azevedo PS, Polegato BF, Minicucci MF, et al. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. Arquivos Brasileiros de Cardiologia; 2016;106:62-69. Go to original source...
    18. Frohlich ED. Risk mechanisms in hypertensive heart disease. Hypertension 1999:782-789. Go to original source...
    19. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: Recent advances in basic science. The Lancet. Lancet Publishing Group; 2011;378:704-712. Go to original source...
    20. Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008; Dec 16;52:2166-2174. Go to original source...
    21. Pascual-Figal DA, Januzzi JL. The biology of ST2: The international ST2 consensus panel. Am J Cardiol. 2015; Apr 2;115:3B-7B. Go to original source...
    22. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007; Jun 1;117:1538-1549. Go to original source...
    23. Parikh RH, Seliger SL, Christenson R, et al. Soluble ST2 for prediction of heart failure and cardiovascular death in an elderly, community-dwelling population. J Am Heart Assoc. 2016; Aug 1;5:8. Go to original source...
    24. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Hear Fail. 2011; Mar;4:180-187. Go to original source...
    25. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: The Framingham heart study. Circulation. 2012; Sep 25;126:1596-1604. Go to original source...
    26. Januzzi JL, Peacock WF, Maisel AS, et al. Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea. Results From the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study. J Am Coll Cardiol. 2007;Aug 14;50:607-613. Go to original source...
    27. Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008; Apr 1;54:752-756. Go to original source...
    28. Friões F, Lourenço P, Laszczynska O, et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol. 2015; Jun 29;104:491-499. Go to original source...
    29. De Boer RA, Yu L, Van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Current Heart Failure Reports. Current Science Inc. 2010;7:1-8. Go to original source...
    30. van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of aminoterminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006; Sep 19;48:1217-1224. Go to original source...
    31. Lok DJA, Van Der Meer P, De La Porte, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol. 2010; May;99:323-328. Go to original source...
    32. Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev; 2013;24:373-384. Go to original source...
    33. Xu X, Li Z, Gao W. Growth differentiation factor 15 in cardiovascular diseases: From bench to bedside. Biomarkers 2011;16:466-475. Go to original source...
    34. Kempf T, Eden M, Strelau J, et al. The transforming growth factor-β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006; Feb;98:351-360. Go to original source...
    35. Lee DH, Yang Y, Lee SJ, et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res. 2003;Aug;63:4648-4655.
    36. Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004; Apr 1;10:2386-2392. Go to original source...
    37. Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth-differentiation factor-15 in heart failure: Relation to disease severity and prognosis in the valsartan heart failure trial. Circulation. 2010; Oct 5;122:1387-1395. Go to original source...
    38. Sharma A, Stevens SR, Lucas J, et al. Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. JACC Hear Fail. 2017;Oct 1;5:724-734. Go to original source...
    39. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A metaanalysis. Am J Kidney Dis. 2002;40:221-226. Go to original source...
    40. Lassus J, Harjola VP, Sund R, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007; Aug;28:1841-1847. Go to original source...
    41. Haase M, Bellomo R, Devarajan P, et al. Accuracy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Diagnosis and Prognosis in Acute Kidney Injury: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2009;Dec;54:1012-1024. Go to original source...
    42. Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinaseassociated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;Jan;16:49-54. Go to original source...
    43. Damman K, van Veldhuisen DJ, Navis G, et al. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail. 2008;Oct;10:997-1000. Go to original source...
    44. Danková M, Mateovičová J, Kalužay J. Význam vyšetrenia lipokalínu asociovaného so želatinázou (NGAL) v moči v diagnostike akútneho obličkového poškodenia u pacientov s akútnym srdcovým zlyhávaním. Cardiol Lett. 2012;21:12-13.
    45. Jougasaki M, Burnett JC. Adrenomedullin: Potential in physiology and pathophysiology. Life Sci; 2000;66:855-872. Go to original source...
    46. Maisel A, Mueller C, Nowak R, et al. Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea. Results From the BACH (Biomarkers in Acute Heart Failure) Trial. J Am Coll Cardiol. 2010; May 11;55:2062-2076. Go to original source...
    47. Bagga S, Bracht J, Hunter S, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 2005;Aug 16;122:553-563. Go to original source...
    48. Lindner K, Haier J, Wang Z, et al. Circulating microRNAs: Emerging biomarkers for diagnosis and prognosis in patients with gastrointestinal cancers. Clinical Science. 2015;128:1-15. Go to original source...
    49. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;Oct 2;18:997-1006. Go to original source...
    50. Liu X, Tong Z, Chen K, et al. The role of miRNA-132 against apoptosis and oxidative stress in heart failure. Biomed Res Int. 2018;2018. Go to original source...
    51. Gómez AM, Valdivia HH, Cheng H, et al. Defective excitationcontraction coupling in experimental cardiac hypertrophy and heart failure. Science (80-) . 1997; May 2;276:800-806. Go to original source...
    52. Kumar R, Woo MA, Birrer BVX, et al. Mammillary bodies and fornix fibers are injured in heart failure. Neurobiol Dis. 2009;Feb;33:236-242. Go to original source...
    53. Neupane B, Zhou Q, Gawaz M, et al. Personalized medicine in inflammatory cardiomyopathy. Personalized Medicine. 2018;15:127-136. Go to original source...
    54. Dludla PV, Dias SC, Obonye N, et al. A systematic review on the protective effect of n-acetyl cysteine against diabetes-associated cardiovascular complications. American Journal of Cardiovascular Drugs. 2018;18:283-298. Go to original source...
    55. Güven Bağla A, Içkin Gülen M, Ercan F, et al. Changes in kidney tissue and effects of erythropoietin after acute heart failure. Biotech Histochem. 2018;Jul 4;93:340-353.
    56. Fang Y, Yeh C. Role of microRNAs in vascular remodeling. Curr Mol Med. 2015;Sep 23;15:684-696. Go to original source...
    57. Villar AV, García R, Merino D, et al. Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int J Cardiol. 2013;167:2875-2881. Go to original source...
    58. Ucar A, Gupta SK, Fiedler J, et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun. 2012;Sep 25;3:1-11. Go to original source...
    59. Täubel J, Hauke W, Rump S, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-inhuman Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021; Jan 7;42:178-188. Go to original source...
    60. Ovchinnikova ES, Schmitter D, Vegter EL, et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail. 2016;Apr 1;18:414-423. Go to original source...
    61. Endo K, Naito Y, Ji X, et al. MicroRNA 210 as a biomarker for congestive heart failure. Biol Pharm Bull. 2013;Jan;36:48-54. Go to original source...
    62. Xiao J, Gao R, Bei Y, et al. Circulating miR-30d predicts survival in patients with acute heart failure. Cell Physiol Biochem. 2017;May 1;41:865-874. Go to original source...
    63. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837-848. Go to original source...
    64. Tang WHW, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circulation Research. 2017;214:11831196. Go to original source...
    65. Peng J, Xiao X, Hu M, et al. Interaction between gut microbiome and cardiovascular disease. Life Sciences. 2018;214:153-157. Go to original source...
    66. Takala J. Determinants of splanchnic blood flow. Br J Anaesth. 1996;77:50-58. Go to original source...
    67. Chioncel O, Ambrosy AP. Trimethylamine N-oxide and risk of heart failure progression: marker or mediator of disease. European Journal of Heart Failure. 2019;21:887-890. Go to original source...
    68. Zhang Y, Wang Y, Ke B, et al. TMAO: how gut microbiota contributes to heart failure. Translational Research. 2021;228:109-125. Go to original source...
    69. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;Apr 7;472:57-65. Go to original source...
    70. Zhu W, Buffa JA, Wang Z, et al. Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine N-oxide-generating pathway, modulates platelet responsiveness and thrombosis risk. J Thromb Haemost. 2018;Sep 1;16:1857-1872. Go to original source...
    71. Tang WHW, Bäckhed F, Landmesser U, et al. Intestinal microbiota in cardiovascular health and disease. JACC State-of-the-Art Review. 2019;73:2089-2105. Go to original source...
    72. Organ CL, Otsuka H, Bhushan S, et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-Oxide, exacerbate pressure overload-induced heart failure. Circ Hear Fail. 2016;Jan 1;9:1. Go to original source...
    73. Li Z, Wu Z, Yan J, et al. Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis. Lab Investig. 2019;Mar 1;99:346-357. Go to original source...
    74. Sun X, Jiao X, Ma Y, et al. Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome. Biochem Biophys Res Commun. 2016;Dec 2;481:63-70. Go to original source...
    75. Tang WHW, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-Noxide in patients with heart failure: Refining the gut hypothesis. J Am Coll Cardiol. 2014;Nov 4;64:1908-1914. Go to original source...
    76. Suzuki T, Heaney LM, Bhandari SS, et al. Trimethylamine N-oxide and prognosis in acute heart failure. Heart. 2016;Jun 1;102:841848. Go to original source...

    Return to the content